Skip to primary content
Skip to secondary content

Biotech 365

Main menu

  • Biotech 365
  • Companies
  • Healthcare Investors
    • Healthcare LPs
  • Healthcare Investors Matchmaking
  • Free DEMO
  • Services
    • Preclinical Studies Database
    • Scientific Due Diligence
    • CRO & CDMO Database
  • Contact

Tag Archives: In Vitro Toxicology

Axiogenesis – in vitro models of healthy and diseased cell types and tissue

Posted on by

Axiogenesis is an international leader in the development and commercialization of in vitro models of healthy and diseased cell types and tissue. Axiogenesis uses stem cells to revolutionize the fields of drug discovery and development.

Axiogenesis – in vitro models of healthy and diseased cell types and tissue

Axiogenesis

Continue reading →

Posted in Biotech Companies, Biotech Companies Germany | Tagged Andreas Engert, Axiogenesis, Axiogenesis - in vitro models of healthy and diseased cell types and tissue, Bernd Fronhoff, Cardiac Hypertrophy, CardioEffect Screening, cardiomyocyte, Cardiomyocytes, Carl-Peter Gerlach, Cor.4U, Cor.At, Disease Modeling, Dopa.4U, drug candidate selection, Electrophysiology, Endo.4M, HCM, Heribert Bohlen, high-throughput screening, HTS, human induced pluripotent stem cell, Human iPS Cells, Hypertrophic Cardiomyopathy, In Vitro Assay Development, in vitro models, in vitro models of healthy and diseased cell types and tissue, In Vitro Toxicology, induced pluripotent stem cells, iPS, iPSC, Klaus Frobel, MEA, Michael Vogel, Microelectrode Array, neuron, Pedro Brugada, Peri.4U, Pluripotent Stem Cells, pre-clinical biotechnology, SMAC.4M, stem cell-based assays, Tissue Modeling

        Services              Healthcare Investors Database              FAQs               CGU               Biotech & Pharma News             Contact
Proudly powered by WordPress